Healthcare AI regulation moved from theory to active enforcement between 2023 and 2026, and developers who are still treating AI compliance as “future work” are increasingly unable to sell into hospitals, payers, or EU markets. This post is a practical map of the regulatory landscape US and international healthcare AI developers need to understand right now.
The Four Regimes Every Healthcare AI Developer Touches
1. FDA Oversight of AI/ML-Enabled Medical Devices
The FDA now reviews AI-enabled devices under its evolving AI/ML framework, including the Predetermined Change Control Plan (PCCP) pathway that allows certain model updates without resubmission. If your software diagnoses, treats, mitigates, or monitors disease, you likely fall in FDA’s jurisdiction regardless of whether you call it “clinical decision support.”
2. HIPAA and the 2024 HIPAA Security Rule Modernization
HHS OCR’s updated Security Rule expectations explicitly address risk analysis for AI systems that process PHI, including training data governance, drift monitoring, and vendor due diligence on AI subcontractors. Developers whose models were trained or fine-tuned on PHI need documented BAAs, minimum-necessary justifications, and de-identification analyses.
3. The EU AI Act for Medical and Health AI
Most AI that qualifies as a medical device under MDR is automatically classified as “high-risk” under the EU AI Act, triggering obligations around risk management, data governance, transparency, human oversight, accuracy, robustness, and cybersecurity. The good news: Article 8 allows integration of AI Act compliance into existing MDR conformity assessment — if you plan for it early.
4. State-Level US Laws and Section 1557
HHS Section 1557 non-discrimination requirements now explicitly cover patient care decision support tools that use AI. State laws — Colorado’s AI Act, California’s emerging rules, Utah, Texas — add layers on automated decision-making, consumer notice, and bias testing.
The Five Compliance Artifacts You Need By Launch
- Intended use statement that survives FDA, EU AI Act, and marketing-claims scrutiny
- Risk management file aligned with ISO 14971 and AI Act Annex IV
- Data governance documentation covering provenance, representativeness, and bias testing
- Transparency package (model card, human-oversight plan, user instructions)
- Post-market monitoring plan covering drift, adverse events, and PCCP change tracking
Common Mistakes We See
- Treating “wellness” framing as a safe harbor when the actual use is clinical
- Using production PHI for model fine-tuning without a compliant BAA and de-identification pathway
- Building separate MDR and AI Act documentation instead of integrated files
- Skipping bias and fairness evaluation until a hospital customer demands it
- Hard-coding model versions so that every improvement becomes a regulatory event
What to Do Next
If you are developing, deploying, or investing in healthcare AI, early legal alignment saves months of downstream rework. See our Healthcare Technology Law Firm — US & International pillar page for a full view of our practice, and contact Global Link Law to discuss a specific product or deployment.
The information provided on this website is for general informational purposes only and should not be considered legal advice. No attorney-client relationship is created by accessing or using this website. Please consult with a qualified attorney before making any legal decisions. Global Link Law is not liable for any reliance on the information provided. Prior results do not guarantee a similar outcome.
